Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma
| dc.contributor.author | Al-Feghali, Karine A. | |
| dc.contributor.author | Youssef, Bassem Y. | |
| dc.contributor.author | Mohamed, Abdallah Sherif Radwan | |
| dc.contributor.author | Hilal, Lara | |
| dc.contributor.author | Smith, Blaine D. | |
| dc.contributor.author | Abu-Gheida, Ibrahim H. | |
| dc.contributor.author | Farha, Georges | |
| dc.contributor.author | Gunn, G. Brandon | |
| dc.contributor.author | Phan, Jack | |
| dc.contributor.author | Lewin, Jan S. | |
| dc.contributor.author | Thekdi, Apurva A. | |
| dc.contributor.author | Morrison, William H. | |
| dc.contributor.author | Garden, Adam Seth | |
| dc.contributor.author | Fuller, Clifton David | |
| dc.contributor.author | Rosenthal, David I. | |
| dc.contributor.department | Radiation Oncology | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T12:12:23Z | |
| dc.date.available | 2025-01-24T12:12:23Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Background: We report outcomes for patients with T2N0M0 glottic squamous cell carcinoma (SCC) treated with radiation therapy (RT). Methods: Patients who received definitive RT for T2 glottic SCC from 2000 through 2013 were retrospectively reviewed. Results: One hundred and thirteen patients were analyzed (median follow-up time 91 months; 85 patients received three-dimensional conformal radiotherapy [3D-CRT] and 28 received intensity-modulated radiation therapy [IMRT]). Fractionation was conventional (58%) or altered (42%); 20 patients (18%) received concurrent chemotherapy. Five-year local control was 83% for the 3D-CRT vs 81% for the IMRT group (P =.76). The ultimate locoregional control at 5 years was 100% for IMRT vs 91% for 3D-CRT (P =.1). The 5-year overall survival (OS) was 78% for 3D-CRT vs 81% for IMRT (P =.83). On multivariate analysis, younger age was the only independent predictor of improved OS (P =.0002). Conclusions: Oncologic and survival outcomes were excellent for patients with T2N0 glottic cancer. Patients treated with IMRT and 3D-CRT had no statistically significant differences in all investigated endpoints. © 2020 Wiley Periodicals, Inc. | |
| dc.identifier.doi | https://doi.org/10.1002/hed.26308 | |
| dc.identifier.eid | 2-s2.0-85085699955 | |
| dc.identifier.pmid | 32484591 | |
| dc.identifier.uri | http://hdl.handle.net/10938/32748 | |
| dc.language.iso | en | |
| dc.publisher | John Wiley and Sons Inc. | |
| dc.relation.ispartof | Head and Neck | |
| dc.source | Scopus | |
| dc.subject | Larynx | |
| dc.subject | Outcomes | |
| dc.subject | Radiotherapy | |
| dc.subject | Survival | |
| dc.subject | T2 | |
| dc.subject | Antineoplastic agent | |
| dc.subject | Radiosensitizing agent | |
| dc.subject | Adult | |
| dc.subject | Aged | |
| dc.subject | Article | |
| dc.subject | Cancer chemotherapy | |
| dc.subject | Cancer radiotherapy | |
| dc.subject | Cancer staging | |
| dc.subject | Cancer survival | |
| dc.subject | Conformal radiotherapy | |
| dc.subject | Female | |
| dc.subject | Follow up | |
| dc.subject | Hoarseness | |
| dc.subject | Human | |
| dc.subject | Intensity modulated radiation therapy | |
| dc.subject | Laryngectomy | |
| dc.subject | Larynx squamous cell carcinoma | |
| dc.subject | Major clinical study | |
| dc.subject | Male | |
| dc.subject | Medical record review | |
| dc.subject | Outcome assessment | |
| dc.subject | Overall survival | |
| dc.subject | Priority journal | |
| dc.subject | Radiation dermatitis | |
| dc.subject | Radiation dose fractionation | |
| dc.subject | Radiotherapy dosage | |
| dc.subject | Retrospective study | |
| dc.subject | Vocal cord disorder | |
| dc.title | Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1